Evaluation of FGFR Alteration Status in Urothelial Tumors

Bahlinger V, Eckstein M, Hartmann A, Stöhr R (2023)

Publication Type: Book chapter / Article in edited volumes

Publication year: 2023

Journal

Methods in Molecular Biology Humana Press

Publisher: Humana Press Inc.

Edited Volumes: Urothelial Carcinoma - Methods and Protocols

Series: Methods in Molecular Biology

Book Volume: 2684

Pages Range: 283-291

DOI: 10.1007/978-1-0716-3291-8_17

Abstract

FGFR alterations in urothelial carcinoma are key driver alterations of tumorigenesis and are long recognized. In 2019 the Food and Drug Administration (FDA) approved the first pan-FGFR inhibitor, as the first specific targeted therapy in urothelial carcinoma. To receive the drug, alteration testing is required, and only alteration carriers can profit of this new agent. Due to this clinical need of detection and analysis of FGFR, here we describe two distinct and specific analytical methodologies: the SNaPshot analysis of nine FGFR3 point mutations and the QIAGEN therascreen^® FGFR RGQ RT-PCR Kit, the FDA-approved companion diagnostic kit.

Authors with CRIS profile

Markus Eckstein Institute of Pathology Arndt Hartmann Lehrstuhl für Allgemeine Pathologie und Pathologische Anatomie Robert Stöhr Medizinische Fakultät

How to cite

APA:

Bahlinger, V., Eckstein, M., Hartmann, A., & Stöhr, R. (2023). Evaluation of FGFR Alteration Status in Urothelial Tumors. In Michèle J. Hoffmann, Nadine T. Gaisa, Roman Nawroth, Thorsten H. Ecke (Eds.), Urothelial Carcinoma - Methods and Protocols. (pp. 283-291). Humana Press Inc..

MLA:

Bahlinger, Veronika, et al. "Evaluation of FGFR Alteration Status in Urothelial Tumors." Urothelial Carcinoma - Methods and Protocols. Ed. Michèle J. Hoffmann, Nadine T. Gaisa, Roman Nawroth, Thorsten H. Ecke, Humana Press Inc., 2023. 283-291.

BibTeX: Download